uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results

uniQure N.V. (NASDAQ:QURE) announced positive topline data from its Phase I/II study of AMT-130 for Huntington’s disease, demonstrating the gene therapy slowed disease progression by 75% over 36 months and was generally well-tolerated. This significant development, in a disease area with no approved therapies, prompted RBC Capital and H.C. Wainwright to reiterate Buy ratings and increase price targets to $65 and $110, respectively. The company, which holds FDA Breakthrough Therapy and RMAT designations for AMT-130, plans to submit a biologics license application in Q1 2026 with a potential US launch later that year.

Analysis

uniQure N.V. (NASDAQ:QURE) recently reported highly positive topline data from its Phase I/II study of AMT-130 for Huntington’s disease, demonstrating the gene therapy slowed disease progression by 75% over 36 months. This pivotal finding, coupled with the treatment being generally safe and well-tolerated, positions AMT-130 as a potential breakthrough in a disease area currently lacking approved therapies to delay onset or slow progression. The FDA has already granted AMT-130 Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations, underscoring its therapeutic potential.

Following these results, prominent research firms significantly upgraded their outlooks for QURE. RBC Capital reiterated a Buy rating and increased its price target from $55 to $65, while H.C. Wainwright raised its price target from $70 to $110, also maintaining a Buy rating. These revised price targets reflect strong analyst confidence in AMT-130's commercial prospects and uniQure's pipeline. The company anticipates submitting a Biologics License Application (BLA) in Q1 2026, targeting a US launch later that year.

The successful Phase I/II data and subsequent analyst upgrades highlight uniQure's strong company fundamentals and its leadership in gene therapy innovation for serious diseases. Given the unmet medical need in Huntington's disease, AMT-130 could significantly alter the treatment landscape, offering substantial market opportunity. The regulatory designations and clear development timeline provide a structured path to commercialization, reinforcing the optimistic sentiment surrounding QURE.

Key Decisions for Investors

• The positive Phase I/II data for AMT-130, coupled with significant analyst price target increases and FDA designations, suggests a strong long-term growth trajectory for uniQure.
• Investors should monitor the progress of the Biologics License Application (BLA) submission in Q1 2026 and subsequent regulatory approvals, as these will be critical catalysts for the stock.
• Given the high unmet medical need in Huntington's disease and AMT-130's potential to be the first disease-modifying therapy, QURE presents a compelling investment opportunity, albeit with inherent biotech development risks.